Table 2.
Expression of surface antigens on peripheral blood monocytes in the studied women
| Laboratory Data | Endometrial Cancer (N = 42) | Cervical Cancer (N = 13) | Ovarian Cancer (N = 14) | Group I (N = 20) | Group II (N = 23) |
|---|---|---|---|---|---|
| CD11a (%) | 99.98 ± 0.06; | 99.94 ± 0.21; | 99.44 ± 1.94; | 99.99 ± 0.05; | 99.96 ± 0.09; |
| 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| (99.74-100.00) | (99.23-100.00) | (92.72-100.00) | (99.79-100.00) | (99.59 -100.00) | |
| CD11b (%) | 99.72 ± 0.73; | 99.35 ± 1.60; | 99.87 ± 0.16; | 99.72 ± 0.45; | 99.91 ± 0.16; |
| 99.87 * | 99.86 * | 99.93 | 99.93 * | 100.00 | |
| (95.28-100.00) | (94.08-100.00) | (99.40-100.00) | (98.07-100.00) | (99.47-100.00) | |
| CD11c (%) | 99.54 ± 1.36; | 97.62 ± 6.74; | 98.27 ± 5.87; | 99.77 ± 0.37; | 99.40 ± 2.37; |
| 100.00 | 99.93 | 100.00 | 99.96 | 100.00 | |
| (92.49-100.00) | 75.38-100.00) | (77.93-100.00) | (98.91-100.00) | (88.63-100.00) | |
| CD16 (%) | 17.86 ± 22.51; | 11.99 ± 18.09; | 26.19 ± 31.96; | 16.99 ± 26.21; | 10.64 ± 4.95; |
| 7.19 | 6.16 * | 8.84 | 6.37 ** | 9.55 | |
| (2.39-83.80) | (1.23-69.87) | (4.24-91.53) | (2.78-85.20) | (5.23-28.30) | |
| CD54 (%) | 83.89 ± 16.44; | 87.27 ± 12.32; | 89.86 ± 11.94; | 92.40 ± 9.16; | 63.82 ± 15.21; |
| 88.46 *** | 91.46 *** | 94.57 *** | 97.00 *** | 65.20 | |
| (27.75-100.00) | (68.40-100.00) | (63.90-100.00) | (69.87-100.00) | (21.61-91.75) | |
| CD62L (%) | 97.64 ± 2.06; | 96.51 ± 4.99; | 98.80 ± 1.51; | 93.69 ± 9.74; | 96.56 ± 2.83; |
| 98.35 | 97.85 | 99.18 *** | 98.23 | 97.01 | |
| (93.00-100.00) | (80.38-99.54) | (94.74-100.00) | (67.94-99.86) | (85.40-99.70) | |
| CD64 (%) | 95.57 ± 9.06; | 93.38 ± 7.42; | 97.88 ± 4.67; | 96.80 ± 5.22; | 99.39 ± 1.19; |
| 99.16 *** | 96.30 ** | 99.65 | 99.59 * | 99.91 | |
| (47.60-100.00) | (76.60-100.00) | (82.13-100.00) | (81.93-100.00) | (95.15-100.00) | |
| HLA-DR (%) | 80.94 ± 15.85; | 68.50 ± 25.66; | 73.98 ± 16.60; | 70.22 ± 24.76; | 94.98 ± 5.66; |
| 85.80 *** | 76.60 *** | 73.35 *** | 79.70 *** | 96.10 | |
| (33.13-99.71) | (18.50-95.83) | (27.65-95.21) | (17.33-99.37) | (73.48-99.63) |
Group I - women operated but had no malignancy in postoperative histopathologic examination, Group II - healthy women. SD - standard deviation, CD - cluster of differentiation molecule, HLA-DR - membrane receptor: Human leukocyte antigen-DR (product of hla-dr locus). Data are presented as: mean ± 1 SD, median (minimum-maximum). Asterisks indicate statistically significant differences in Mann–Whitney U test: * - p < 0.05; ** - p < 0.01; *** - p < 0.001, in comparison to Group II.